The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst)
 
Anish Thomas
No Relationships to Disclose
 
John J. Nemunaitis
Employment - Gradalis
Leadership - Gradalis
Stock and Other Ownership Interests - Gradalis
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca
Speakers' Bureau - Amgen; AstraZeneca
Patents, Royalties, Other Intellectual Property - Gradalis
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Baxalta; Takeda
 
Manish R. Patel
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
 
Jaafar Bennouna
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
 
Franklin Chen
Honoraria - Celgene
 
Jean-Pierre Delord
No Relationships to Disclose
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; ARIAD
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Lilly/ImClone (Inst); MedImmune (Inst); OncoMed (Inst)
 
Matthew H. Taylor
Honoraria - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis; Trillium Therapeutics
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis; Trillium Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Eisai
Travel, Accommodations, Expenses - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Trillium Therapeutics
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Corvus Pharmaceuticals; Curis; EMD Serono; Genentech/Roche; Incyte; Lilly/ImClone; Macrogenics; Seagen; Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Claire F. Verschraegen
No Relationships to Disclose
 
Hans Juergen Grote
Employment - Merck KGaA
 
Anja von Heydebreck
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Kevin M. Chin
Employment - EMD Serono
Leadership - EMD Serono
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - EMD Serono
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Celgene (Inst); EMD Serono (Inst); Pfizer (Inst)